Retrospective analysis of gefitinib combined with carboplatin plus pemetrexed for NSCLC with activating EGFR mutations

被引：0
|
作者：
Tsurumi, K. [1 ]
Suzuki, A. [1 ]
Watanabe, K. [1 ]
Fukuhara, T. [1 ]
机构：
[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.415
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P39-7
引用
收藏
页码：S1378 / S1378
页数：1
相关论文
共 50 条
  • [41] Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
    Xiaoyang Zhai
    Wanhu Li
    Ji Li
    Wenxiao Jia
    Wang Jing
    Yaru Tian
    Shuhui Xu
    Yuying Li
    Hui Zhu
    Jinming Yu
    Radiation Oncology, 16
  • [42] Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
    Zhai, Xiaoyang
    Li, Wanhu
    Li, Ji
    Jia, Wenxiao
    Jing, Wang
    Tian, Yaru
    Xu, Shuhui
    Li, Yuying
    Zhu, Hui
    Yu, Jinming
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [43] Rh-endostatin combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in NSCLC: A retrospective comparison with standard chemotherapy
    Zhou, Shengyu
    Shi, Yuankai
    Zuo, Lijie
    He, Xiaohui
    Pi, Jinping
    Jin, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Long-term survival of NSCLC patients with EGFR mutations treated with EGFR TKIs gefitinib or erlotinib
    Janne, R
    Sequist, L
    Lindeman, N
    Bell, D
    Huberman, M
    Meyerson, M
    Haber, D
    Lynch, T
    Johnson, B
    LUNG CANCER, 2005, 49 : S109 - S109
  • [45] Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
    Hayashi, Hidetoshi
    Nadal, Ernest
    Gray, Jhanelle E.
    Ardizzoni, Andrea
    Caria, Nicola
    Puri, Tarun
    Grohe, Christian
    CLINICAL LUNG CANCER, 2022, 23 (01) : E69 - E82
  • [46] Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with NSCLC
    Ikesue, Hiroaki
    Watanabe, Hiroyuki
    Hirano, Megumi
    Chikamori, Ayako
    Suetsugu, Kimitaka
    Ryokai, Yuriko
    Egashira, Nobuaki
    Koichi, Takayama
    Yoichi, Nakanishi
    Masuda, Satohiro
    ANNALS OF ONCOLOGY, 2015, 26 : 96 - 96
  • [47] A Phase II Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed in Elderly Patients with Advanced Non-Squamous NSCLC
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Goto, Koichi
    Yoh, Kiyotaka
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Tanaka, Hiroshi
    Abe, Tetsuya
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S316 - S316
  • [48] Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics
    Feng, Wei
    Chen, Xi
    Guan, Shao-xing
    Ruan, Hong-lian
    Huang, Yan
    Zhang, Hui-zhen
    Yang, Yun-peng
    Fang, Wen-feng
    Zhao, Hong-yun
    Zhuang, Wei
    Xin, Shuang
    Chen, You-hao
    Wang, Fei
    Gao, Yue
    Huang, Min
    Wang, Xue-ding
    Zhang, Li
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (07) : 1857 - 1864
  • [49] The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
    Xin, Shuang
    Zhao, Yuanyuan
    Wang, Xueding
    Huang, Yan
    Zhang, Jing
    Guo, Ying
    Li, Jiali
    Li, Hongliang
    Ma, Yuxiang
    Chen, Lingyan
    Hu, Zhihuang
    Huang, Min
    Zhang, Li
    SCIENTIFIC REPORTS, 2015, 5
  • [50] The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
    Shuang Xin
    Yuanyuan Zhao
    Xueding Wang
    Yan Huang
    Jing Zhang
    Ying Guo
    Jiali Li
    Hongliang Li
    Yuxiang Ma
    Lingyan Chen
    Zhihuang Hu
    Min Huang
    Li Zhang
    Scientific Reports, 5
12345